Monogram edges closer to HIV market:
This article was originally published in Clinica
Executive Summary
Monogram Biosciences has taken yet another step closer to marketing its HIV test for predicting response to a new type of drug being developed by Pfizer, after the pharmaceutical was issued an approvable letter by the US FDA. Its co-receptor tropism assay, Trofile, was used to select the more than 2,000 clinical trial patients worldwide who have received treatment with the drug - a CCR5-antagonist called maraviroc. Trofile will be made commercially available after the drug has received a definitive approval, which is pending the resolution of outstanding questions and the finalisation of product labelling between Pfizer and the FDA.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.